Ribokis 200 mg Tablet
Generic Name: Ribociclib
Brand Name: Ribokis
Strength: 200 mg
Form: Film-coated Oral Tablet
Pack Size: Commonly 21 tablets per pack
Manufacturer: Everest Pharmaceuticals
Distributed by: NP Molecule
Indications:
Ribokis (Ribociclib) is indicated for the treatment of:
-
Hormone receptor-positive (HR+), HER2-negative advanced or metastatic breast cancer
In combination with:-
An aromatase inhibitor as initial endocrine-based therapy
-
Fulvestrant in patients with disease progression following endocrine therapy
-
Applicable for both pre/perimenopausal and postmenopausal women, and in men.
Pharmacology:
Ribociclib is a selective cyclin-dependent kinase (CDK) 4/6 inhibitor.
It inhibits CDK4 and CDK6, proteins that regulate cell cycle progression.
By blocking these kinases, Ribokis prevents the proliferation of cancer cells, especially in HR+ breast cancers which are dependent on cell cycle signaling.
Dosage & Administration:
-
Recommended dose: 600 mg once daily (i.e., 3 tablets of 200 mg)
-
Administered for 21 consecutive days, followed by 7 days off, in a 28-day cycle
-
Taken with or without food
-
Tablets should be swallowed whole, not crushed or chewed
Dose modifications may be necessary based on side effects and blood counts.
Drug Interactions:
-
Avoid strong CYP3A4 inhibitors and inducers
-
QT interval–prolonging drugs should be used with caution
-
Monitor ECG and electrolytes if used with interacting medications
Contraindications:
-
Hypersensitivity to Ribociclib or any tablet component
-
Use with caution in patients with known QT prolongation
Side Effects:
-
Common: Neutropenia, nausea, fatigue, diarrhea, hair loss, liver enzyme elevations
-
Serious: QT prolongation, hepatotoxicity, severe neutropenia, infections
Pregnancy & Lactation:
-
Contraindicated during pregnancy due to potential fetal harm
-
Breastfeeding should be avoided during treatment and for at least 3 weeks after the last dose
Precautions & Warnings:
-
Perform baseline and periodic ECG and liver function tests
-
Regularly monitor complete blood count (CBC)
-
Advise contraception for women of reproductive potential during and after therapy
Overdose Effects:
-
Increased risk of hematologic toxicities and QT prolongation
-
Symptomatic treatment and close monitoring required
Therapeutic Class:
-
CDK 4/6 Inhibitor
-
Targeted Therapy for HR+/HER2– Breast Cancer
Storage Conditions:
-
Store below 30°C in a dry place
-
Protect from light and moisture
-
Keep out of reach of children
